Interestingly, EP300 also has tumor suppressor effects in several different clinically relevant MDS models driven by mutations in epigenetic regulators TET2, ASXL1, and SRSF2, respectively, inhibiting the malignant transition of MDS to AML [27,94]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.